Biodesix, Inc. (BDSX) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong revenue growth, improved gross margins, and a significant reduction in net loss, which are positive indicators. The Q&A section reveals confidence in achieving adjusted EBITDA positivity and a positive outlook on capital needs. However, there are some concerns regarding competition and unclear responses on specific financial metrics. Overall, the positive aspects outweigh the negatives, leading to a positive sentiment rating.
Key Financial Performance
Total Revenue $21.8 million, a 20% increase over the prior year. The increase is attributed to growth in lung diagnostic testing revenue and development services revenue.
Lung Diagnostic Testing Revenue $19.8 million from approximately 15,700 tests, compared to $17.2 million from approximately 13,900 tests in the third quarter of 2024. This represents 13% growth in test volumes and 16% growth in revenue. The growth is due to increased test adoption and higher average revenue per test.
Development Services Revenue $1.9 million, representing 97% year-over-year growth. The growth is attributed to strong interest in partnership service offerings and an increase in contracts under development services.
Gross Margin Percentage 81%, up 400 basis points from 77% in the third quarter of 2024. The improvement is due to operational efficiencies and process improvements.
Operating Expense (Excluding Direct Costs and Expenses) $24.7 million, a 10% increase over the third quarter of 2024 but a 4% decrease versus the second quarter of 2025. The increase year-over-year is due to scaling operations, while the quarter-over-quarter decrease reflects cost-conscious measures.
SG&A Expense $21.7 million, an 8% increase year-over-year but a 3% decrease versus the second quarter of 2025. The increase is due to scaling the sales team, while the decrease reflects operational efficiencies.
R&D Expense $3.0 million, a $500,000 increase year-over-year but a $300,000 decrease from the second quarter of 2025. The increase is due to investments in clinical studies and pipeline advancement.
Net Loss $8.7 million, an improvement of 15% year-over-year and 24% over the second quarter of 2025. The improvement is due to revenue growth and cost management.
Adjusted EBITDA Loss of $4.6 million, an improvement of 18% year-over-year and 36% over the second quarter of 2025. The improvement is attributed to revenue growth and operational efficiencies.
Unrestricted Cash and Cash Equivalents $16.6 million, impacted by timing of collections, a $5.2 million increase in accounts receivable, and net cash inflows of $4.8 million from the ATM facility.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Nodify Lung Testing: Expanded into primary care, increasing test orders from primary care by 75% year-over-year. Total tests ordered grew to 15,700, up 13% year-over-year. Average revenue per test improved by 7%.
Development Services: Revenue grew 97% year-over-year to $1.9 million. Contracted revenue reached $12.9 million, a 16% increase year-over-year.
MRD Test: Presented multiple updates on the combination proteomic and genomic MRD test at various conferences.
Primary Care Expansion: Expanded access to 50% of patients with pulmonary nodules managed in primary care. Increased primary care test orders from 4% to 11%.
Partnerships: Expanded product development partnership with Bio-Rad Laboratories for high-complexity in vitro diagnostic assays.
Revenue Growth: Total revenue increased by 20% year-over-year to $21.8 million. Lung diagnostic testing revenue grew by 16%.
Gross Margins: Improved gross margins by 400 basis points to 81%.
Adjusted EBITDA: Improved by 18% year-over-year, with a loss of $4.6 million.
Sales Team Expansion: Increased sales reps to an average of 85 in Q3, with plans to grow to 93-97 in Q4.
Digital Ordering: Increased digital test ordering by 43% year-over-year, enhancing customer retention.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Medicare Advantage plans payment issues: Several Medicare Advantage plans had instituted administrative barriers to paying claims for Medicare-covered tests. Although one of the largest plans restarted paying for current claims, older claims remain unresolved, impacting revenue collection.
Supply cost pressures and macroeconomic uncertainty: Despite achieving strong gross margins, the company faces continued supply cost pressures and macroeconomic uncertainties, which could affect profitability and operational stability.
Patient compliance challenges: The company faces challenges in ensuring patient compliance for blood draws, particularly when patients need to schedule blood draws at another time or location, potentially impacting test completion rates.
Scaling sales team: The company is expanding its sales team, which increases operational costs. While this is aimed at driving growth, it poses a risk if the additional sales reps do not achieve expected productivity levels.
Regulatory and reimbursement hurdles: The company is involved in clinical validation and regulatory submissions for new diagnostic assays, which could face delays or challenges, impacting the timeline for new product launches.
Economic uncertainties affecting collections: Timing of collections has impacted cash flow, as seen in the $5.2 million increase in accounts receivable, which could pose liquidity risks if not managed effectively.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2025: The company has increased its revenue guidance range for 2025 to $84 million to $86 million, based on strong third-quarter performance and early fourth-quarter momentum.
Adjusted EBITDA: The company expects to achieve adjusted EBITDA positivity in the fourth quarter of 2025, supported by strong gross margins and increased sales team productivity.
Gross Margins: Gross margins are expected to remain near 80% for the remainder of 2025, despite supply cost pressures and macroeconomic uncertainties.
Sales Team Expansion: The company plans to have an average of 93 to 97 sales representatives in the field in the fourth quarter of 2025 and anticipates adding approximately 6 representatives per quarter in 2026 to drive patient access to diagnostic testing.
Development Services Revenue: The company reported $1.9 million in development services revenue for Q3 2025, a 97% year-over-year growth, and exited the quarter with $12.9 million under contract, representing a 16% increase over the prior year.
Pipeline Development: The company is advancing its product development pipeline, including a combination proteomic and genomic MRD test, expanded indications for VeriStrat, and digital diagnostics. It has also expanded its partnership with Bio-Rad Laboratories for high-complexity in vitro diagnostic assays.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you talk about some of the signals or proof points that your primary care expansion is working?
A:Scott Hutton explained that the primary care expansion is not about cold calling but involves pulmonologists introducing them to their referral network. They are seeing earlier detection and diagnosis by primary care physicians, which they believe will have a significant long-term impact. They plan to share more data in the coming months.
Q:What can you share about expanding your product portfolio as we move into 2026?
A:Scott Hutton mentioned their excitement about the AMP R&D Day, where partners like Bio-Rad, Thermo Fisher, and Memorial Sloan Kettering will participate. They plan to highlight their product development pipeline and share updates on ongoing efforts, aiming to commercialize additional tests in the future.
Q:Could you elaborate on the ramp-up of new sales reps and peak average sales per rep at full productivity?
A:Scott Hutton stated that the ramp-up of new sales reps has been consistent, with a target of $1 million per sales rep in productivity. They plan to expand to 50 territories by Q4 2026, hiring about 6 sales reps per quarter, and aim to leverage access into primary care for further growth.
Q:Do you feel that increased direct competition in the lung cancer testing space is necessary to push milestones forward?
A:Scott Hutton acknowledged the challenges in the lung cancer testing space but emphasized their first-mover advantage. He supports broader awareness and believes that increased competition and new tests will benefit early detection and diagnosis, ultimately raising the standard of care.
Q:Would you be willing to quantify the amount of Medicare Advantage back pay received in the third quarter?
A:Robin Cowie clarified that they did not receive much back pay in Q3 but started receiving consistent payments on new claims. There was no unusual revenue from back claims in Q3.
Q:How sustainable is the uptick in ASP going forward?
A:Robin Cowie stated that consistent payment on Medicare Advantage claims is expected to continue, and they will call out any back claims to provide a normalized ASP view.
Q:Of the increase in the guide, how much is due to diagnostic revenue versus services revenue?
A:Robin Cowie explained that the increase is heavily tied to diagnostic revenue, which constitutes the majority of the company's revenue.
Q:What is your confidence level in reaching adjusted EBITDA positivity in Q4, and what are your views on capital needs over the next few years?
A:Robin Cowie expressed confidence in reaching adjusted EBITDA positivity in Q4, citing strong performance and revenue growth. They feel good about their capital position and are driving towards profitability without significant additional capital needs.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the peak average sales per rep at full productivity and the exact amount of Medicare Advantage back pay received in Q3, using general statements instead of precise figures.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Bio Rad
Blair LLC
Canaccord Genuity
Corp Research
Director
Division Canaccord
Division Lake
Genuity Corp
Hutton Chief
LLC Research
MRD test
Markets LLC
Memorial Sloan
Nodify testing
Research Division
Sloan Kettering
assay
development service
evidence
increase account
increase decrease
intervention
ordering
presentation Dr
product development
rep field
sensitivity specificity
test care
testing pulmonologists
update product
use
webinar
BDSX Transcript
Biodesix, Inc. (BDSX) Q1 2026 Earnings Call Transcript
Positive5-4
The earnings call shows strong financial performance with a 25% revenue increase and improved gross margins. Despite a net loss, the reduction from the previous year and improved cash flow are positive indicators. The lack of discussion on strategic initiatives or returns suggests no new concerns or changes. The overall sentiment is positive, predicting a 2% to 8% stock price increase.
Biodesix, Inc. (BDSX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-11
Biodesix, Inc. (BDSX) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call reveals strong revenue growth, improved gross margins, and reduced net loss, indicating positive financial performance. The company's increased revenue guidance and expected EBITDA positivity further support a positive outlook. Despite the lack of explicit risk discussion, the operational efficiencies and strategic sales team expansion highlight proactive management. The absence of shareholder return plans or Q&A insights limits the rating to 'Positive', but the overall financial health and optimistic guidance suggest a favorable stock price movement.
Biodesix, Inc. (BDSX) Q3 2025 Earnings Call Transcript
Positive11-3
The earnings call highlights strong revenue growth, improved gross margins, and a significant reduction in net loss, which are positive indicators. The Q&A section reveals confidence in achieving adjusted EBITDA positivity and a positive outlook on capital needs. However, there are some concerns regarding competition and unclear responses on specific financial metrics. Overall, the positive aspects outweigh the negatives, leading to a positive sentiment rating.
BDSX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
